Jpmorgan Chase & CO Mersana Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,351,359 shares of MRSN stock, worth $5.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,351,359

Previous 1,976,899 18.94%

Holding current value

$5.41 Million

Previous $3.97 Million 11.86%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$1.23 - $2.25 $460,585 - $842,535	374,460 Added 18.94%	2,351,359 $4.44 Million
Q2 2024 Aug 12, 2024	BUY	$2.0 - $4.45 $1.1 Million - $2.45 Million	549,559 Added 38.5%	1,976,899 $3.97 Million
Q1 2024 May 10, 2024	BUY	$2.16 - $5.94 $2.91 Million - $8.01 Million	1,348,517 Added 1710.82%	1,427,340 $6.39 Million
Q4 2023 Feb 12, 2024	SELL	$1.11 - $2.34 $208,893 - $440,369	-188,192 Reduced 70.48%	78,823 $182,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $3.91 $1.25 Million - $4.6 Million	-1,176,779 Reduced 81.51%	267,015 $339,000
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $4.07 Million - $12.6 Million	1,322,229 Added 1087.67%	1,443,794 $4.75 Million
Q1 2023 May 18, 2023	BUY	$4.0 - $7.02 $459,520 - $806,457	114,880 Added 1718.47%	121,565 $499,000
Q1 2023 May 11, 2023	SELL	$4.0 - $7.02 $1.52 Million - $2.67 Million	-380,138 Reduced 98.27%	6,685 $27,000
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $1.85 Million - $2.57 Million	326,697 Added 543.35%	386,823 $2.27 Million
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $1.81 Million - $3.13 Million	-391,013 Reduced 86.67%	60,126 $406,000
Q2 2022 Aug 11, 2022	BUY	$2.84 - $5.0 $401,888 - $707,550	141,510 Added 45.7%	451,139 $2.09 Million
Q1 2022 May 11, 2022	BUY	$3.74 - $6.63 $1.04 Million - $1.84 Million	278,047 Added 880.4%	309,629 $1.24 Million
Q4 2021 Feb 10, 2022	BUY	$5.48 - $9.86 $350 - $631	64 Added 0.2%	31,582 $197,000
Q3 2021 Nov 12, 2021	BUY	$8.56 - $14.47 $269,794 - $456,065	31,518 New	31,518 $297,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $223M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Mersana Therapeutics, Inc. Transaction History